Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Lichen Planus and Lichen Planopilaris
NCT05030415Phase 1Completed
- Sponsor
- The University of New Mexico
- Start
- Aug 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixekizumab in lichen planus (LP), lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA), sponsored by The University of New Mexico. Primary endpoint: Investigator Global Assessment at 16 weeks. Started Aug 2021; status: completed.
02
Drugs
ixekizumab
03
Conditions
lichen planus (LP)lichen planopilaris (LPP)frontal fibrosing alopecia (FFA)
Beyond the preview
Go deeper on NCT05030415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05030415.